AUPH
NASDAQ · Biotechnology
Aurinia Pharmaceuticals Inc
$14.41
+0.20 (+1.41%)
Open$14.54
Previous Close$14.21
Day High$14.70
Day Low$14.40
52W High$16.54
52W Low$6.83
Volume—
Avg Volume1.30M
Market Cap1.90B
P/E Ratio6.63
EPS$2.08
SectorBiotechnology
Analyst Ratings
Buy
13 analysts
Price Target
+182.0% upside
Current
$14.41
$14.41
Target
$40.64
$40.64
$34.07
$40.64 avg
$61.77
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 274.24M | 213.73M | 554.79M |
| Net Income | 278.26M | 195.18M | -143,878,553 |
| Profit Margin | 101.5% | 96.4% | -25.9% |
| EBITDA | 120.48M | 89.21M | -183,212,536 |
| Free Cash Flow | — | — | -112,933,113 |
| Rev Growth | +28.3% | +28.3% | +6.7% |
| Debt/Equity | 0.12 | 0.12 | 0.45 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $207.18 | +0.96% | 166.6 | 397.77B |
| AMGN | Amgen Inc | $353.93 | +1.58% | 24.4 | 188.06B |
| GILD | Gilead Sciences Inc | $138.26 | +0.11% | 20.0 | 170.34B |
| VRTX | Vertex Pharmaceuticals Inc | $454.97 | +1.42% | 29.2 | 115.53B |
| REGN | Regeneron Pharmaceuticals | $749.47 | +1.05% | 17.9 | 80.50B |
| ALNY | Alnylam Pharmaceuticals Inc | $328.70 | +6.70% | 139.7 | 43.84B |